Roanna Ruiz
Stock Analyst
(0.99)
# 1,898
Out of 4,648 analysts
57
Total ratings
32.26%
Success rate
-19.57%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $5.18 | +151.21% | 3 | Oct 25, 2024 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $21 → $25 | $15.40 | +62.34% | 3 | Sep 20, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.95 | +135.49% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $375.37 | -12.09% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $51.72 | +12.14% | 1 | Aug 15, 2023 | |
| CORT Corcept Therapeutics | Initiates: Market Perform | $25 | $50.47 | -50.47% | 1 | Apr 11, 2023 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Perform | $49 | $11.09 | +341.84% | 10 | Feb 9, 2023 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $5 | $3.26 | +53.37% | 4 | Jan 27, 2023 | |
| VIR Vir Biotechnology | Maintains: Outperform | $45 → $43 | $9.33 | +360.88% | 3 | Jan 27, 2023 | |
| SCPH scPharmaceuticals | Maintains: Outperform | $12 → $13 | $4.02 | +223.38% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.39 | +77.25% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $18.19 | +4.48% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $116.51 | +3.00% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $9.61 | +420.29% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3 → $2 | $0.61 | +227.87% | 6 | Oct 19, 2022 |
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $5.18
Upside: +151.21%
ARS Pharmaceuticals
Sep 20, 2024
Maintains: Outperform
Price Target: $21 → $25
Current: $15.40
Upside: +62.34%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.95
Upside: +135.49%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $375.37
Upside: -12.09%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $51.72
Upside: +12.14%
Corcept Therapeutics
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $50.47
Upside: -50.47%
Enanta Pharmaceuticals
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $11.09
Upside: +341.84%
Xeris Biopharma Holdings
Jan 27, 2023
Maintains: Outperform
Price Target: $6 → $5
Current: $3.26
Upside: +53.37%
Vir Biotechnology
Jan 27, 2023
Maintains: Outperform
Price Target: $45 → $43
Current: $9.33
Upside: +360.88%
scPharmaceuticals
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $4.02
Upside: +223.38%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.39
Upside: +77.25%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $18.19
Upside: +4.48%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $116.51
Upside: +3.00%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $9.61
Upside: +420.29%
Oct 19, 2022
Maintains: Market Perform
Price Target: $3 → $2
Current: $0.61
Upside: +227.87%